Optimizing NK-92 serial killers: gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy.

Navarrete-Galvan L, Guglielmo M, Cruz Amaya J, Smith-Gagen J, Lombardi VC, Merica R, Hudig D

Open source

DOI
10.1186/s12967-022-03350-6
Published
2022 Apr 2
Container
Journal of translational medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12967-022-03350-6,
  title = {Optimizing NK-92 serial killers: gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy.},
  author = {Navarrete-Galvan L and Guglielmo M and Cruz Amaya J and Smith-Gagen J and Lombardi VC and Merica R and Hudig D},
  year = {2022},
  journal = {Journal of translational medicine},
  doi = {10.1186/s12967-022-03350-6},
  url = {https://doi.org/10.1186/s12967-022-03350-6}
}

RIS

TY  - JOUR
TI  - Optimizing NK-92 serial killers: gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy.
AU  - Navarrete-Galvan L
AU  - Guglielmo M
AU  - Cruz Amaya J
AU  - Smith-Gagen J
AU  - Lombardi VC
AU  - Merica R
AU  - Hudig D
PY  - 2022
JO  - Journal of translational medicine
DO  - 10.1186/s12967-022-03350-6
UR  - https://doi.org/10.1186/s12967-022-03350-6
ER  - 

APA

L, N., M, G., J, C. A., J, S., VC, L., R, M., & D, H. (2022). Optimizing NK-92 serial killers: gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy.. Journal of translational medicine. https://doi.org/10.1186/s12967-022-03350-6

Source records